In the OASIS-1 study, 13% of participants (people with obesity without diabetes) receiving oral semaglutide 50 mg experienced altered skin sensation events compared to 1% with placebo - these events were generally mild to moderate in severity, occurred during dose escalation to the higher doses and resolved without requiring permanent treatment discontinuation [21]
Their major mechanisms of action are slowing of gastric emptying, hunger suppression, increased insulin and decreased glucagon secretion from the pancreas
Early note: I bold one phrase for clarity, because many readers search that exact term
PMCID: PMC11311305
Its purpose, in a properly conducted research workflow, is to allow analytical chemists, contract research organizations, and academic laboratories to characterize the compound by HPLC, by mass spectrometry, by stability studies and to use it as a comparator in their own assays